Christina Lynne Race, PA-C

Dawes Fretzin Clinical Research Group, LLC
7910 North Shadeland Avenue
Indianapolis, Indiana 46256
Phone (317) 516-5030
Fax (317) 516-5148
E-mail: christinadfcrg@gmail.com

Dawes Fretzin Dermatology Group, LLC
7910 North Shadeland Avenue
Indianapolis, Indiana 46256
Phone (317) 516-5000
Fax (317) 516-5146

Education

Butler University (Indianapolis, IN)
Bachelor of Health Science/Physician Assistant, 2000
- Dean's List
- Graduated with Honors

Professional Experience

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Sub-Investigator, 2004-Present

Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Physician Assistant, 2000-Present

Indiana Blood Center/Tissue Bank (Indianapolis, IN)
Donor Procurement, 1999-00

Methodist Hospital Emergency Department (Indianapolis, IN)
Emergency Room Technician, 1997-98

License/Certifications

Indiana State Physician Assistant License 10000471A
NCCAA 1045335
CPR/AED Certified
ACLS Certified
TB Certified
Adjunct Faculty Butler University
CITI Certification, March 2010, May 2012, February 2014, February 2015, February 2016, February 2017, February 2018, January 2021

C. Race PA-C
8/22/22

Professional Societies

Membership to the American Academy of Physician Assistants
Membership to the Society of Dermatology Physician Assistants
Membership to the Indiana Academy of Physician Assistants
House of Delegates Student Representative for Physician Assistant organization (Butler University)
Fundraising chair for Butler University Methodist Physician Assistant organization (Butler University)

Psoriatic Arthritis

Sponsor: Janssen Research and Development
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis April 2015 to Present

Sponsor: Janssen Research and Development
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Psoriatic Arthritis August 2014 to September 2015

Sponsor: Novartis Pharmaceuticals
A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 3 years in subjects with active Psoriatic Arthritis June 2014 to Present

Atopic Dermatitis

Sponsor: Pfizer
A Phase 2B Randomized, Double-Blind, Placebo-Controlled, Parallel, Multicenter, Dose-Ranging, Study to Evaluate the Efficacy and Safety Profile of PF-04965842 in subjects with Moderate to Severe Atopic Dermatitis.April 2016- Present

Sponsor: GlaxoSmithKline
A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the T reatment of Atopic Dermatitis - February 2016 to Present

Sponsor: MedImmune, Limited
A Phase 2a, Randomized, Double-blinded, Placebocontrolled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis August 2015 to September 2016

Sponsor: Regeneron Pharmaceuticals
A Phase 3, Randomized, Doulbe-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis July 2015 to February 2017

Sponsor: Regeneron Pharmaceuticals
An Open-Label Study of Dupilumab In Patients with Atopic Dermatitis Who Participated In Previous Dupilumab Clinical Trials - June 2015 to Present

Sponsor: Regeneron Pharmaceuticals
A phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis February 2015 to June 2016

Sponsor: Regeneron Pharmaceuticals
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis Treated with Dupilumab September 2014 to December 2015

Christina Lynne Race, PA-C

Actinic Keratosis

Sponsor: Therapeutics, Inc
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of a Generic Ingenol Mebutate Gel, 0.015% and Picato Gel, 0.015% in Subjects with Actinic Keratosis on the Face or Scalp July 2016 to Present

Sponsor: LEO Pharma A/S
Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest – M*ay 2015 to Present*

Sponsor: Perrigo UK Finco Limitetd Par
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo UK Finco Ingenol Mebutate Topical Gel 0.015% to Leo Pharma Inc. Picato® Topical Gel 0.015% (Ingenol Mebutate Topical Gel 0.015%), and Both Active Treatments to a Vehicle Control in the Treatment of Actinic Keratosis on the Head Region (Face or Scalp) March 2015 to December 2015

Sponsor: Leo Pharma A/S
Safety of LEO 43204 0.018%, 0.037% and 0.1% for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and trunk/extremities, respectively – F*ebruary 2015 to September 2015*

Common Warts

Sponsor: RXi Pharmaceuticals
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone) on the Clearance of Verruca Vulgaris (Common Warts) in Subject Ages 18-65 Years. July 2016 – Current